POST-TEST

Gastrointestinal Cancer Tumor Panel: Clinical Investigators Provide Their Perspectives on Current Cases and Clinical Issues in the Management of Colorectal, Gastric and

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 1. The Phase III TML trial evaluating 5. The results from the Phase III beyond disease progression RECOURSE trial of TAS-102 for patients for patients with metastatic colorectal with metastatic colorectal cancer cancer demonstrated a statistically refractory to standard therapies demon- significant improvement in overall strated a statistically significant improve- survival (OS) with bevacizumab beyond ment in ______with TAS-102/best progression compared to chemotherapy supportive care compared to placebo/ alone. best supportive care. a. True a. OS b. False b. Progression-free survival c. Both a and b 2. Similar to those with other agents in d. Neither a nor b the same class, the adverse events of note that were associated with the VEGF 6. Results from the Phase II RECAP trial inhibitor on the RAISE trial of capecitabine in combination with include ______. ______or placebo as second-line a. Bleeding/hemorrhage therapy for patients with metastatic b. Hypertension pancreatic cancer indicated improved c. Proteinuria OS with that agent in a subgroup of d. Both a and b patients with high C-reactive protein levels. e. All of the above a. Ruxolitinib 3. The ongoing Phase III JACOB trial is b. Brivanib evaluating chemotherapy/ c. Nanoparticle albumin-bound (nab) with or without ______as first-line paclitaxel therapy for patients with HER2-positive metastatic gastric or gastroesophageal- 7. The Phase III ______trial junction cancer. evaluated surgery followed by treatment a. Lapatinib with gemcitabine versus neoadjuvant b. Afatinib gemcitabine/oxaliplatin followed by surgery and adjuvant gemcitabine for c. patients with resectable pancreatic cancer. 4. Which of the following was among the most problematic toxicities associated a. Alliance A021101 with the use of regorafenib in the Phase b. NEOPAC III CORRECT study, which demonstrated c. ESPAC-5 a significant benefit with regorafenib compared to placebo in patients with 8. The Phase III KEYNOTE-061 trial will metastatic colorectal cancer? evaluate ______versus paclitaxel as a. Fatigue second-line therapy for advanced gastric b. Hand-foot syndrome or gastroesophageal adenocarcinoma. c. Myalgia a. d. Both a and b b. e. All of the above c. Pidilizumab POST-TEST

Gastrointestinal Cancer Tumor Panel: Clinical Investigators Provide Their Perspectives on Current Cases and Clinical Issues in the Management of Colorectal, Gastric and Pancreatic Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 9. The STAT3 and Nanog pathways are 10. Results from the Phase II OLIVIA trial of important targets blocked by the investi- FOLFOX/bevacizumab versus FOLFOXIRI/ gational agent ______in Phase I bevacizumab indicated superior relapse- to III studies in gastric cancer. free survival with ______. a. Defactinib a. FOLFOXIRI/bevacizumab b. Tarextumab b. FOLFOX/bevacizumab c. BBI-608 c. Neither a nor b